Kåre Schultz, Teva CEO (Christopher Goodney/Bloomberg via Getty Images)

Te­va of­fi­cial­ly shut­ters the doors to a trou­bled South­ern Cal­i­for­nia site

While FDA in­ves­ti­ga­tors ear­li­er this year found is­sues at Te­va Phar­ma­ceu­ti­cals’ plant in Irvine, CA, forc­ing the com­pa­ny to pad­lock the doors, the com­pa­ny has de­cid­ed to pull the plug on re­open­ing it.

Ac­cord­ing to a Cal­i­for­nia Work­er Ad­just­ment and Re­train­ing No­ti­fi­ca­tion (WARN) no­tice, Te­va is ax­ing 305 jobs at the site, which has had a mul­ti­tude of is­sues, and per­ma­nent­ly clos­ing it.

Last year the site re­ceived a Form 483 from the FDA that led to the re­call of more than 2.5 mil­lion vials of drugs that might not be ster­ile. The in­spec­tion found that un­treat­ed wa­ter dam­age like­ly led to mold gen­er­at­ing in the walls, and Te­va took a few steps to pre­vent the fur­ther spread of mold and bac­te­ria through­out the site.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.